Series A

(CDMO): iVexSol started their company at MBI in 2019 with 3 employees. Through seed investment funding from the Massachusetts Life Sciences Center and the support of the MBI team, iVexSol graduated from MBI in 2022 with 20+ employees and has raised $40M to date. They moved to their new site in Lexington, Massachusetts where they continue to grow and thrive. iVexSol’s mission is to improve patients’ lives by developing transformative vector production technologies that will enable and accelerate the discovery of new medicines and increase patient access to vital cell and gene therapies.